Jennifer A. Simonovich
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jennifer A. Simonovich has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin G. Keselowsky
J. Crayton Pruitt Family Department of Biomedical Engineering University of Florida Gainesville Florida USA
3 shared publications - Edward A. Phelps
J. Crayton Pruitt Family Department of Biomedical Engineering University of Florida Gainesville Florida USA
3 shared publications - Gregory A. Hudalla
J. Crayton Pruitt Family Department of Biomedical Engineering University of Florida Gainesville Florida USA
3 shared publications - Madeline J. Fuchs
J. Crayton Pruitt Family Department of Biomedical Engineering University of Florida Gainesville Florida USA
2 shared publications - Abhishek P. Shrestha
Department of Surgery, College of Medicine, University of Florida, Gainesville, FL 32608, USA
1 shared publication - Adrienne E. Widener
J. Crayton Pruitt Family Department of Biomedical Engineering University of Florida Gainesville Florida USA
1 shared publication
Latest Publications
- 1 November 2026
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 114 (11)
Localized IDO Delivery via Granular PEG Hydrogel Enhances Therapeutic Control of Psoriasis
Enzyme therapeutics are often limited by poor stability, rapid clearance, and systemic effects that reduce therapeutic efficacy and necessitate high dosing. Enzyme‐biomaterial conjugation can address these limitations and improve outcomes by localizing therapeutics at the tissue site of intended action. In particular, indoleamine 2,3‐dioxygenase (IDO), a potent immunomodulatory enzyme, has demonstrated therapeutic effectiveness when retained locally at sites of inflammation through fusion to a carbohydrate‐binding protein. Here, we report a complementary biomaterial‐mediated delivery strategy to prolong retention time and investigate efficacy in an imiquimod‐induced model of psoriasis. IDO maintained enzyme activity after bioconjugation to polyethylene glycol maleimide (PEG‐MAL) microgels. Localized delivery of IDO‐conjugated microgels reduced psoriatic scores compared to soluble IDO or unconjugated microgels. Additionally, fibrotic capsule thickness decreased 30% in the IDO‐conjugated microgel group compared to the unconjugated microgel. These findings demonstrate the efficacy of localized IDO delivery via covalent attachment to granular hydrogels, which may serve as a platform for other immunomodulatory enzymes.
- 1 November 2026
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 114 (11)
Localized IDO Delivery via Granular PEG Hydrogel Enhances Therapeutic Control of Psoriasis
Enzyme therapeutics are often limited by poor stability, rapid clearance, and systemic effects that reduce therapeutic efficacy and necessitate high dosing. Enzyme‐biomaterial conjugation can address these limitations and improve outcomes by localizing therapeutics at the tissue site of intended action. In particular, indoleamine 2,3‐dioxygenase (IDO), a potent immunomodulatory enzyme, has demonstrated therapeutic effectiveness when retained locally at sites of inflammation through fusion to a carbohydrate‐binding protein. Here, we report a complementary biomaterial‐mediated delivery strategy to prolong retention time and investigate efficacy in an imiquimod‐induced model of psoriasis. IDO maintained enzyme activity after bioconjugation to polyethylene glycol maleimide (PEG‐MAL) microgels. Localized delivery of IDO‐conjugated microgels reduced psoriatic scores compared to soluble IDO or unconjugated microgels. Additionally, fibrotic capsule thickness decreased 30% in the IDO‐conjugated microgel group compared to the unconjugated microgel. These findings demonstrate the efficacy of localized IDO delivery via covalent attachment to granular hydrogels, which may serve as a platform for other immunomodulatory enzymes.
- Open Access
- 8 July 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (28)
Circulating PEG-indoleamine 2,3-dioxygenase ameliorates diverse inflammatory diseases without toxicity or compromising immunocompetence.
Indoleamine 2,3-dioxygenase (IDO), the enzyme responsible for tryptophan catabolism, is protective in many autoimmune and inflammatory diseases. We previously developed a localized immunomodulation approach through the fusion of IDO to a carbohydrate binding protein [E. Bracho-Sanchez et al., Nat. Biomed. Eng. 7, 1156-1169 (2023)]. Here we further develop IDO as a protein therapeutic for inflammation, investigating systemic delivery via conjugation of poly(ethylene glycol) (PEG) to IDO. PEGylation extended circulation time and treatment PEG-IDO demonstrated therapeutic efficacy in five autoimmune and inflammatory models. Treatment with a single dose of PEG-IDO resulted in reversal of hind limb paralysis in experimental autoimmune encephalomyelitis as model of multiple sclerosis; protected against hepatic damage in liver ischemia-reperfusion injury; prevention of abdominal aortic aneurysm; and decreased severity of imiquimod-induced psoriasis. Treatment with two doses of PEG-IDO provided maintenance of body weight and colon length in acute ulcerative colitis. PEG-IDO treatment increased regulatory T cell populations and reduced pathogenic Th17 cell populations and inflammatory cytokine production. Systemic delivery of PEG-IDO had little-to-no off-target effects. Mice maintained immunocompetency, clearing the Listeria monocytogenes infection, and had no observed toxicity. Additionally, PEG-IDO increased serum kynurenine, consistent with a kynurenine-mediated mechanism of action. These findings demonstrate systemic immunomodulation via circulating PEG-IDO ameliorates a breadth of disparate autoinflammatory diseases, protecting against inflammation-driven tissue destruction in spinal cord, liver, abdominal aorta, skin, and colon, while presenting a positive safety profile, and expanding the scope of potential applications for this therapeutic approach.
- 8 July 2026
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 123 (28)
Open AccessCirculating PEG-indoleamine 2,3-dioxygenase ameliorates diverse inflammatory diseases without toxicity or compromising immunocompetence.
Indoleamine 2,3-dioxygenase (IDO), the enzyme responsible for tryptophan catabolism, is protective in many autoimmune and inflammatory diseases. We previously developed a localized immunomodulation approach through the fusion of IDO to a carbohydrate binding protein [E. Bracho-Sanchez et al., Nat. Biomed. Eng. 7, 1156-1169 (2023)]. Here we further develop IDO as a protein therapeutic for inflammation, investigating systemic delivery via conjugation of poly(ethylene glycol) (PEG) to IDO. PEGylation extended circulation time and treatment PEG-IDO demonstrated therapeutic efficacy in five autoimmune and inflammatory models. Treatment with a single dose of PEG-IDO resulted in reversal of hind limb paralysis in experimental autoimmune encephalomyelitis as model of multiple sclerosis; protected against hepatic damage in liver ischemia-reperfusion injury; prevention of abdominal aortic aneurysm; and decreased severity of imiquimod-induced psoriasis. Treatment with two doses of PEG-IDO provided maintenance of body weight and colon length in acute ulcerative colitis. PEG-IDO treatment increased regulatory T cell populations and reduced pathogenic Th17 cell populations and inflammatory cytokine production. Systemic delivery of PEG-IDO had little-to-no off-target effects. Mice maintained immunocompetency, clearing the Listeria monocytogenes infection, and had no observed toxicity. Additionally, PEG-IDO increased serum kynurenine, consistent with a kynurenine-mediated mechanism of action. These findings demonstrate systemic immunomodulation via circulating PEG-IDO ameliorates a breadth of disparate autoinflammatory diseases, protecting against inflammation-driven tissue destruction in spinal cord, liver, abdominal aorta, skin, and colon, while presenting a positive safety profile, and expanding the scope of potential applications for this therapeutic approach.
- Open Access
- 19 September 2025
- Published by Royal Society of Chemistry (RSC) in Molecular Systems Design & Engineering
- Vol. 10 (12) , 1090-1098
Engineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations
Indoleamine 2,3-dioxygenase is an immunomodulatory enzyme that shows great promise when delivered exogenously as a protein therapeutic. However, IDO activity is under complex redox control, mediated in part by multiple cysteine residues within its primary sequence. We have characterized three IDO mutants in which solvent-accessible cysteine residues were mutated to chemically-similar serine residues, “IDOC4S4” with C112S, C159S, C206S, and C308S mutations and “IDOC5S3” with C112S, C159S, and C308S mutations based on prior reports that C206 is necessary for catalytic function, and IDOC0S8, in which all cysteine residues were mutated to serines. IDOC0S8 was expressed in poor yield and demonstrated less than 1% activity when compared to wild-type IDO. In contrast, IDOC4S4 and IDOC5S3 demonstrated robust enzymatic activity, though IDOC5S3 had a slower Vmax than wild-type and IDOC4S4. Computational predictions and experimental measurements suggested a high degree of structural similarity between the wild-type IDO and IDOC4S4, with subtle perturbation of α-helical content for IDOC5S3. The structure of IDOC0S8 was predicted to be significantly different than that of wild-type IDO. IDOC4S4 and IDOC5S3 were more stable than wild-type IDO over time at physiological, ambient, and reduced temperatures, likely due to diminished oxidation of the mutant IDO forms. Based on the increased Vmax and robust thermal stability of IDOC4S4, we fused it to the anchoring moiety galectin 3, to evaluate its effectiveness in a mouse model of psoriasis. The IDOC4S4-galectin-3 fusion blunted the rate and severity of disease as compared to wild-type IDO-galectin-3 fusion. When compared to historical data with Cys-Ala IDO mutants, this study highlights the importance of employing amino acid substitution according to similarity in isosteric and isostructural shape to advance IDO as an immunomodulatory therapeutic.
- 19 September 2025
- Published by Royal Society of Chemistry (RSC) in Molecular Systems Design & Engineering
- Vol. 10 (12) , 1090-1098
Open AccessEngineering an indoleamine 2,3-dioxygenase immunotherapy via selective cysteine-to-serine mutations
Indoleamine 2,3-dioxygenase is an immunomodulatory enzyme that shows great promise when delivered exogenously as a protein therapeutic. However, IDO activity is under complex redox control, mediated in part by multiple cysteine residues within its primary sequence. We have characterized three IDO mutants in which solvent-accessible cysteine residues were mutated to chemically-similar serine residues, “IDOC4S4” with C112S, C159S, C206S, and C308S mutations and “IDOC5S3” with C112S, C159S, and C308S mutations based on prior reports that C206 is necessary for catalytic function, and IDOC0S8, in which all cysteine residues were mutated to serines. IDOC0S8 was expressed in poor yield and demonstrated less than 1% activity when compared to wild-type IDO. In contrast, IDOC4S4 and IDOC5S3 demonstrated robust enzymatic activity, though IDOC5S3 had a slower Vmax than wild-type and IDOC4S4. Computational predictions and experimental measurements suggested a high degree of structural similarity between the wild-type IDO and IDOC4S4, with subtle perturbation of α-helical content for IDOC5S3. The structure of IDOC0S8 was predicted to be significantly different than that of wild-type IDO. IDOC4S4 and IDOC5S3 were more stable than wild-type IDO over time at physiological, ambient, and reduced temperatures, likely due to diminished oxidation of the mutant IDO forms. Based on the increased Vmax and robust thermal stability of IDOC4S4, we fused it to the anchoring moiety galectin 3, to evaluate its effectiveness in a mouse model of psoriasis. The IDOC4S4-galectin-3 fusion blunted the rate and severity of disease as compared to wild-type IDO-galectin-3 fusion. When compared to historical data with Cys-Ala IDO mutants, this study highlights the importance of employing amino acid substitution according to similarity in isosteric and isostructural shape to advance IDO as an immunomodulatory therapeutic.
- 1 June 2021
- Published by Elsevier in Biomaterials
- Vol. 273, 120808
In vitro generation of peri-islet basement membrane-like structures
- 1 June 2021
- Published by Elsevier in Biomaterials
- Vol. 273, 120808
In vitro generation of peri-islet basement membrane-like structures
- 1 April 2019
- Published by Elsevier in Biomaterials
- Vol. 198, 49-62
Engineered microenvironments and microdevices for modeling the pathophysiology of type 1 diabetes
- 1 April 2019
- Published by Elsevier in Biomaterials
- Vol. 198, 49-62
Engineered microenvironments and microdevices for modeling the pathophysiology of type 1 diabetes